Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
3.740
-0.330 (-8.11%)
At close: May 11, 2026, 4:00 PM EDT
3.800
+0.060 (1.60%)
Pre-market: May 12, 2026, 7:44 AM EDT
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$657,313
Market Cap
308.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | 152 | 30 | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Abeona Therapeutics | 226 |
| Nautilus Biotechnology | 130 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Lineage Cell Therapeutics | 77 |
| Rezolute | 75 |
| Immuneering | 53 |
REPL News
- 3 days ago - Replimune jumps on news FDA chief behind RP1 rejection may be removed - TheFly
- 6 days ago - FDA Commissioner Makary defends agency's decision on Replimune's drug - Reuters
- 19 days ago - US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection - Reuters
- 19 days ago - Replimune rises after Wall Street Journal editorial defending RP1 - TheFly
- 4 weeks ago - Replimune downgraded to Neutral from Outperform at Wedbush - TheFly
- 4 weeks ago - Replimune downgraded to Market Perform from Outperform at Leerink - TheFly
- 4 weeks ago - Replimune downgraded to Sell from Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Replimune downgraded to Underweight from Neutral at JPMorgan - TheFly